Q1 Earnings Estimate for ZNTL Issued By HC Wainwright

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued on Tuesday, November 11th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.49) EPS.

A number of other research firms also recently issued reports on ZNTL. Morgan Stanley dropped their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Finally, Wells Fargo & Company dropped their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.03.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $1.34 on Wednesday. The company’s fifty day moving average price is $1.54 and its 200-day moving average price is $1.45. The firm has a market capitalization of $96.66 million, a price-to-earnings ratio of -0.65 and a beta of 1.87. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.12.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its position in Zentalis Pharmaceuticals by 150.6% in the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock valued at $4,244,000 after purchasing an additional 1,606,802 shares during the last quarter. Nuveen LLC bought a new stake in Zentalis Pharmaceuticals during the 1st quarter valued at $807,000. Tybourne Capital Management HK Ltd. boosted its position in Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after buying an additional 516,666 shares during the period. GSA Capital Partners LLP grew its holdings in Zentalis Pharmaceuticals by 275.9% in the 1st quarter. GSA Capital Partners LLP now owns 541,975 shares of the company’s stock worth $862,000 after acquiring an additional 397,805 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Zentalis Pharmaceuticals by 46.2% in the first quarter. American Century Companies Inc. now owns 46,900 shares of the company’s stock valued at $75,000 after acquiring an additional 14,816 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.